Home › Furiex Pharmaceuticals Announces Positive Top-Line Results Of Two Pivotal Phase III Clinical Trials Of Eluxadoline In Patients With IBS-d
 

Keywords :   


Furiex Pharmaceuticals Announces Positive Top-Line Results Of Two Pivotal Phase III Clinical Trials Of Eluxadoline In Patients With IBS-d

2014-02-05 07:38:22| drugdiscoveryonline Home Page

Furiex Pharmaceuticals, Inc. recently announced top-line results indicating the company’s two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain

Tags: with results iii positive

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.06Atlantic Tropical Weather Outlook
30.06Eastern North Pacific Tropical Weather Outlook
30.06Hurricane Beryl Graphics
30.06Hurricane Beryl Public Advisory Number 6A
30.06Summary for Hurricane Beryl (AT2/AL022024)
30.06Hurricane Beryl Graphics
30.06Hurricane Beryl Wind Speed Probabilities Number 6
30.06Hurricane Beryl Public Advisory Number 6
More »